Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Estrone sulfate
Drug ID BADD_D00835
Description Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.
Indications and Usage Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
Marketing Status Discontinued
ATC Code G03CA07; G03CC04
DrugBank ID DB04574
KEGG ID D00312
MeSH ID C017296
PubChem ID 3001028
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms estrone sulfate | oestrone sulphate | estrone-3-sulfate | estrone sulfate, 16-(14)C-labeled | Evex | estrone sulfate, potassium salt | potassium estrone sulfate | estrone sulfate, sodium salt | sodium estrone sulfate | estrone sulfate, 14C-labeled | estrone sulfate, ammonium salt
Chemical Information
Molecular Formula C18H22O5S
CAS Registry Number 481-97-0
SMILES CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Ectropion of cervix21.06.01.004--Not Available
Endometrial cancer21.07.02.002; 16.12.02.001--Not Available
Endometrial hyperplasia21.07.01.002--Not Available
Endometrial hypertrophy21.07.01.003--Not Available
Epilepsy17.12.03.002--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum10.02.01.020; 23.07.02.001--Not Available
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Fibrocystic breast disease21.05.01.002; 16.14.01.003--Not Available
Flatulence07.01.04.002--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gallbladder disorder09.03.02.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Haemangioma24.03.06.004; 16.02.01.002--Not Available
Headache17.14.01.001--
Hirsutism05.05.01.005; 23.02.04.001--
Hypersensitivity10.01.03.003--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypocalcaemia14.04.01.004--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages